Do you have any questions? Contact us.
Supplementary protection certificate for medicinal products
The European Union intends to provide sufficient protection for the development of medicinal products in the interest of public health and also to encourage pharmaceutical research. In view of the above, this Regulation creates a supplementary protection certificate for medicinal products at Community level which makes it possible to rectify disparities in the national systems.
Regulation (EC) No of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (codified version) (Text with EEA relevance).
The purpose of the supplementary protection certificate for medicinal products is to remedy the disparities and shortcomings in national patenting systems for pharmaceutical research. It aims in particular to guarantee sufficient protection for the development of medicinal products in the European Union (EU).
Indeed, the period between the filing of a patent application for a new medicinal product and authorisation to place it on the market constitutes one of the factors which actually reduces the effective protection afforded by the patent and can compromise the amortisation of investment in research. The lack of sufficient protection can also lead research centres based in the Member States to relocate to countries offering better protection.
In order to also guarantee the free movement of medicinal products, the supplementary certificate for the protection of medicinal products also aims to prevent the development of too many disparities in national legislation.
The certificate is issued if the product for which it was requested, as a medicinal product and at the time when the application was filed in a Member State, meets the following conditions:
- the product * is protected by a basic patent * in force;
- the product, as a medicinal product, has been granted a marketing authorisation;
- the product has not already been the subject of a certificate;
- the marketing authorisation is the first authorisation to place the product on the market as a medicinal product.
Furthermore, the certificate applies to the product in the same way as the patent from which it benefits. The Regulation also specifies the arrangements relating to application for and granting of the certificate and likewise the conditions for lapse, invalidity and publicity of the certificate.
The certificate cannot be granted for a period exceeding five years. Furthermore, the duration of protection afforded by a patent and by the certificate cannot exceed 15 years overall for the holder's first marketing authorisation.
This Regulation codifies and repeals Regulation (EEC) No 1768/92.
|Act||Entry into force||Deadline for transposition in the Member States||Official Journal|
|Regulation (EEC) No 469/2009||
OJ L152 of 16.6.2009